p class=text>With an eye on penetrating the diagnostic sector, therapeutics firm Ribozyme Pharmaceuticals Inc. reached a deal with a major Japanese company.Ribozyme entered into an agreement with Fujirebio Inc. to develop and commercialize ribozyme-based clinical diagnostic products, marking the first significant union between Ribozyme and its allosteric ribozyme platform technology with a diagnostics company. Read More
Aegera Therapeutics Inc. raised C$17 million (US$10.7 million) in a private round of financing, which it will use to move its XIAP antisense program into Phase I trials in cancer next year. (BioWorld Today) Read More
